Developer of artificial intelligence and computational medicine technologies
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.
Visit website: https://benevolent.ai/
People at BenevolentAI
9 Computational Drug Discovery Startups Using AI
Nanalyze - 25-Apr-2017
Including BenevolentAI which already has 24 drug candidates. 98% of big data has only been creat...Read more...